Imunon, Inc. (IMNN)

Kritische 8-K Meldungen

DatumMeldungSchwereFilingAuszug
07.01.2026Item 5.02 — Abgang SchlüsselpersonenHOCHSEC            Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
14.06.2023Item 5.02 — Abgang SchlüsselpersonenHOCHSEC            Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer
03.01.2023Item 5.02 — Abgang SchlüsselpersonenHOCHSEC            Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer

Stammdaten

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.

Unternehmen & Branche

NameImunon, Inc.
TickerIMNN
CIK0000749647
BoerseUS
SektorHealthcare
IndustrieBiotechnology
SIC2834 · Pharmaceutical Preparations

Wertpapier & Kennzahlen

CUSIP
ISIN
TypCommon Stock
Marktkapitalisierung6,9 Mio. USD
Beta2,12
Dividendenrendite0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

PeriodeFilingUmsatzNettoergebnisEPSAktivaEigenkapital
2025-12-3110-K-14,495,028-6.8312,288,1167,061,876
2025-09-3010-Q-3,429,124-1.168,987,7334,081,724
2025-06-3010-Q-2,740,559-2.158,788,3272,659,850
2025-03-3110-Q-4,102,495-0.286,862,086452,028
2024-12-3110-K-18,620,242-16.949,717,3644,244,298
2024-09-3010-Q-4,845,475-3.7614,391,1908,191,721
2024-06-3010-Q-4,788,017-7.649,691,4963,741,234
2024-03-3110-Q-4,929,525-0.5214,324,7688,499,743
2023-12-3110-K-19,514,977-2.1621,918,06913,387,642
2023-09-3010-Q-3,476,614-0.3724,654,42818,071,742
2023-06-3010-Q-5,558,865-0.6128,721,69421,515,140
2023-03-3110-Q-5,591,365-0.6842,106,19626,646,956
2022-12-3110-K500,000-35,898,234-5.0343,975,89429,327,866
2022-09-3010-Q125,000-6,148,290-0.8760,531,10741,351,075
2022-06-3010-Q125,000-6,042,937-0.8765,327,97547,042,493
2022-03-3110-Q125,000-10,474,33264,341,38646,265,209
2021-12-3110-K500,000-20,769,25074,046,79955,795,931
2021-09-3010-Q125,000-5,410,54479,468,51759,341,181
2021-06-3010-Q125,000-5,448,39783,010,00264,053,512
2021-03-3110-Q125,000-5,689,00373,041,03554,960,058

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.

Hinweis

Erweitert ×